SciRhom

SciRhom GmbH is a leading biotechnology company with the vision of translating advanced scientific discoveries into therapies that transform autoimmune diseases. Based on a detailed understanding of how key cell surface proteases control inflammation, SciRhom is closely collaborating with Professor Carl Blobel from the Hospital for Special Surgery in New York City (USA) to develop a first-in-class humanized iRhom2 antibody. SciRhom was founded in 2016 through a collaboration between academic and industry scientists with extensive experience in antibody development.